Edition:
United States

Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

5.40USD
9 Dec 2016
Change (% chg)

$0.26 (+5.06%)
Prev Close
$5.14
Open
$5.14
Day's High
$5.43
Day's Low
$4.99
Volume
84,496
Avg. Vol
27,882
52-wk High
$10.97
52-wk Low
$3.55

Summary

Name Age Since Current Position

Peter Friedli

62 Chairman of the Board

David Dresner

68 2016 Interim President and Chief Executive Officer

Gregory Law

49 2015 Chief Financial Officer, Corporate Secretary and Treasurer

Frank Czworka

46 2014 Vice President, General Manager of Wound Care

Adrian Mollo

41 2014 General Counsel

R. Alberto Avendano

55 2016 Chief Medical Officer

Alla Danilkovitch

51 2015 Chief Scientific Officer

Thomas Brandt

63 2016 Independent Director

Jay Moyes

62 2006 Independent Director

Aziz Ahmad

IR Contact

Biographies

Name Description

Peter Friedli

Mr. Peter Friedli is Chairman of the Board of Osiris Therapeutics, Inc. Mr. Friedli has been a director of Osiris since January 1996, except for the period between February and June 2004. Since 1986, he has been a principal of the investment-banking firm Friedli Corporate Finance, Inc., a leading Swiss venture capital firm which has made significant investments in the biotechnology industry and has been the primary source of financing for Osiris. Mr. Friedli is also the President and a director of New Venturetec Ltd., a Swiss publicly traded investment company. Mr. Friedli has extensive experience as an independent investment manager in venture capital and has specialized in investments domiciled in the United States in the areas of biotechnology and technology. Previously, he worked in the field of international management consulting for service and industrial companies in Europe and the United States. He serves as a director in certain private companies. Mr. Friedli's business experience and service on the boards of other companies and organizations, and particularly his longtime commitment to Osiris and extensive experience in finance, enable him to contribute extensively to the work of the Osiris board.

David Dresner

Mr. David A. Dresner is Interim President and Chief Executive Officer of the Company, effective June 9, 2016. Mr. Dresner is Co-Founder and Chief Financial Officer of the Dresner Group, an information technology consulting firm, and has been engaged by the Company in a consulting capacity focusing on accounting and finance matters since April of this year. He began his career at Price Waterhouse Coopers (“PWC”) where he served for 20 years in various capacities, including audit partner and managing partner of the firm’s Baltimore office. After leaving PWC, Mr. Dresner served in senior management capacities for a several commercial enterprises, including Statoil Energy, Inc. for which he was President and Chief Executive Officer, and as CFO for a coronary stent developer, Micell Technologies, which received regulatory approval for its first biomedical device and commercially launched in Europe last year.

Gregory Law

Mr. Gregory I. Law has been promoted as Chief Financial Officer, Corporate Secretary and Treasurer of the Company. He was Vice President - Finance of the Company. Mr. Law has over 25 years of finance and accounting experience in a variety of industries. Prior to joining Osiris, Mr. Law was a Principal with Garland Group, where he provided consulting services to public and private companies in the areas of interim CFO and Controllership, financial reporting, mergers & acquisitions, valuation and compliance. Previously, Mr. Law held positions at McQuadeBrenan LLP, CRC Results, Control Solutions International, XO Communications, MCI and General Electric. He is graduated from Virginia Tech with a BS in Accounting and earned his MBA from George Washington University.

Frank Czworka

Mr. Frank D. Czworka, Jr. is a Vice President, General Manager of Wound Care and was promoted to Vice President in February 2014. Mr. Czworka has over 20 years of sales and marketing experience in the Life Science industry with a demonstrated track record of building specialty sales forces and developing product access in managed markets, including public and private payer accounts. Mr. Czworka worked for Auxillium Pharmaceuticals in a commercial leadership role from 2009 through 2011. He spent the majority of his biotech career at MedImmune, LLC where he held multiple commercial positions of increasing responsibility including Vice President of Sales. He was at MedImmune, LLC from 2000 through 2009. He has a BS BA degree in Marketing from the University of Central Florida.

Adrian Mollo

Mr. Adrian P. Mollo is a General Counsel of the company. Mr. Mollo's background spans a broad spectrum of legal areas and he has extensive experience working with both established and emerging growth companies. Mr. Mollo has served as the lead partner for intellectual property licensing and transactions and as Vice Chair of the Intellectual Property Department for over fifteen years at the Washington, D.C. office of McKenna Long & Aldridge LLP. Mr. Mollo holds a J.D. from the University of South Carolina School of Law, where he graduated magna cum laude, and a B.A. from Winthrop University.

R. Alberto Avendano

Dr. R. Alberto Avendano, M.D. serves as Chief Medical Officer of the Company. Dr. Avendano received his license to practice medicine almost 30-years ago. From June 2013 until joining Osiris, Dr. Avendano served as the Medical Director for Indivior Inc. (previously Reckitt Benckisser Pharmaceuticals). Prior to joining Indivior, Dr. Avendano served in a variety of medical director and research positions, most recently as Associate Medical Director at EMD Serono, Inc.

Alla Danilkovitch

Dr. Alla N. Danilkovitch, Ph.D., has been promoted as Chief Scientific Officer of the Company. She was Vice President, Research and Development of the company. Dr. Danilkovitch has over 25 years of broad biomedical research experience including stem cell biology, immunology and cancer research. She has a proven record of successful product development from scientific ideas to market launch, which includes the world's first approved stem cell drug, Prochymal, for graft versus host disease as well as Osiris' current line of products. Prior to joining Osiris, Dr. Danilkovitch conducted research at the following institutions: National Cancer Institute of National Institutes of Health, Max-Plank Institute of Biochemistry in Munich (Germany), Eotvos Lorand University in Budapest (Hungary) and Moscow State University (Russia). Dr. Danilkovitch earned a Ph.D. degree in cell biology and an M.S. degree in cellular immunology and microbiology from the Moscow State University. She also holds a R.N. degree in pediatrics with an intensive care experience at Moscow's province general hospital in Russia.

Thomas Brandt

Mr. Thomas M. Brandt Jr., is Independent Director of the Company. Mr. Brandt served as a board member for TeleCommunication Systems Inc. (TCS; NASDAQ:TSYS) from 2009 until its sale to Comtech Telecommunications in February, 2016, and was Chief Financial Officer for the company beginning in 1997. He led TCS through an IPO in 2000 and helped the company grow from $25 million of revenue in 1998 to nearly $400 million in 2015. Prior to his role at TeleCommunication Systems, Mr. Brandt was CFO of Digex, Inc., an internet service provider, where he helped lead its 1996 IPO. Earlier in his career, he worked in the audit practice of Price Waterhouse for 12 years. He has more than three decades of experience enhancing corporate performance through alignment of corporate finance strategies with organizational objectives. Mr. Brandt currently serves as a member of the boards of Antenna Research Associates and the YMCA of Central Maryland, as well as on Silicon Valley Bank’s CFO Advisory Board. Mr. Brandt is a CPA with a bachelor’s degree in management science from Duke University and an MBA from the Wharton School of the University of Pennsylvania.

Jay Moyes

Mr. Jay M. Moyes is an Independent Director of Osiris Therapeutics, Inc. From May 2008 through July 2009, Mr. Moyes joined the Board of Directors of Puma Biotechnology, Inc.(NYSE: PBYI), where he serves as the Chairman of the Compensation and Corporate Governance Committees and is a member of the Audit Committee. Mr. Moyes' extensive background in finance and accounting in the context of the life sciences industry enables him to make significant contributions to our Board in general, and particularly to the Audit Committee.

Aziz Ahmad

Basic Compensation